FDA Approval, Global Partnerships, and IPOs: Bio Ventures Enter Full-Fledged Growth Phase

Bio companies fostered in the Hongneung Small-scale Research and Development Special Zone (Hongneung Small-scale Special Zone) in Seoul are achieving a series of results, including obtaining approval from the U.S. Food and Drug Administration (FDA), signing exclusive global distribution agreements, attracting large-scale investments, and pursuing initial public offerings (IPOs). The technology commercialization support system that connects industry, academia, research institutes, and hospitals is being recognized as a successful model for the domestic bio-startup ecosystem, as it leads to actual commercialization and investment.


The Korea Institute of Science and Technology (KIST) announced on July 13 that the Hongneung Small-scale Special Zone, which is jointly operated with Kyung Hee University and Korea University, has proven the effectiveness of full-cycle support for technology commercialization based on the global achievements of resident companies.

Endorobotics. Provided by KIST

Endorobotics. Provided by KIST

View original image

A prime example is Endorobotics, a surgical robotics company. Endorobotics became the first Korean medical robotics firm to obtain the U.S. FDA approval code (NAY) in the same category as the global surgical robot 'Da Vinci.' The company also signed an exclusive global distribution agreement with Olympus, the world's largest endoscope company. Including a strategic investment of 10 billion won from Olympus, Endorobotics has secured a total of 32.5 billion won in Series C funding.


Gene therapy company Elixigen is also on a growth trajectory with its AAV-based macular degeneration treatment, effective with a single administration. Elixigen was the first in Korea to receive U.S. FDA Fast Track designation for an AAV therapy, raised a cumulative 88 billion won in investments, and is seeking a technology-special listing on KOSDAQ this year.


'One-stop support' from R&D to investment and listing


Neocan Bio is a research institute spin-off that has commercialized osteoarthritis treatment technology using medical hemp components, based on joint research with KIST. At the end of last year, the company began construction of Korea's first GMP manufacturing facility for hemp active pharmaceutical ingredients (APIs) in the Andong Industrial Hemp Regulation-Free Special Zone in Gyeongbuk, with an investment of 13 billion won. Through this, it established a wide-area cooperation model, with R&D in Hongneung and production in Andong.

Neocen Bio. Provided by KIST

Neocen Bio. Provided by KIST

View original image

All three companies received full-cycle support from the Hongneung Small-scale Special Zone, covering everything from technology startups to research and development, clinical validation, investment attraction, and preparation for listing. Among Korea's 14 small-scale special zones, Hongneung is the only one jointly operated by three core technology institutions—KIST, Kyung Hee University, and Korea University—and serves as a specialized R&D hub for bio-innovation.


Through an investment council comprising 29 investment institutions, a growth-stage support system has been established, covering everything from seed investment and Series C funding to technology-special listings. Based on these achievements, Hongneung Small-scale Special Zone received the highest rating of 'Excellent' for two consecutive years in the Ministry of Science and ICT’s 2025 annual evaluation of small-scale special zones. The total investment attracted by companies in the zone reached 75.4 billion won, 460% of the target, the highest among all small-scale special zones nationwide.



Osang Rok, President of KIST, said, "KIST's advanced fundamental technologies are leading to the founding and commercialization of research institute spin-offs. Going forward, we will nurture Hongneung as a global bioindustry hub by integrating advanced technologies such as quantum, robotics, and artificial intelligence (AI) with medical and bio fields."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing